If you or a loved one is taking Tysabri, understanding the early signs of PML can be lifesaving. While this medication effectively manages multiple sclerosis or Crohn's disease, it carries a rare but serious risk of progressive multifocal leukoencephalopathy. Building on decades of research into immunosuppressive therapies, this page outlines the clinical red flags that warrant immediate medical attention.
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The prognosis for patients who develop PML while on Tysabri is poor, and the condition is often permanent. The U.S. Food and Drug Administration (FDA) has issued a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and post-marketing surveillance. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks, and both had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of 1043 patients with Crohn's disease evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The prognosis for PML is grim. The FDA label states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This means that even if a patient survives the acute infection, they are likely to have permanent neurological deficits. These deficits can include cognitive impairment, motor dysfunction, vision loss, and speech difficulties. The permanence of these effects is due to the nature of the infection, which destroys oligodendrocytes—the cells that produce myelin in the brain. Myelin loss leads to irreversible damage to nerve fibers, resulting in lasting disability. Several risk factors increase the likelihood of developing PML in Tysabri-treated patients. These include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The presence of anti-JCV antibodies indicates prior exposure to the JC virus, which is necessary for PML to develop. Longer treatment duration increases the cumulative risk, as the drug's mechanism of action—blocking immune cell trafficking to the brain—creates a permissive environment for viral reactivation. Prior immunosuppressant use further compromises the immune system, increasing vulnerability.
The timeline between Tysabri exposure and PML diagnosis can vary. In clinical trials, PML occurred after a median of 120 weeks of treatment in multiple sclerosis patients, and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has also been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation. The FDA recommends that patients continue to be monitored for any new signs or symptoms that may be suggestive of PML for at least six months following discontinuation of Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that the risk does not immediately resolve upon stopping the drug, and delayed onset is possible.
The adequacy of warnings regarding Tysabri and PML is reflected in the FDA's boxed warning and the restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning clearly states the risk of PML and the factors that increase it. The TOUCH program requires prescribers and patients to be enrolled and to follow specific monitoring protocols. This includes withholding Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For multiple sclerosis patients, an MRI scan should be obtained prior to initiating therapy, which may help differentiate subsequent multiple sclerosis symptoms from PML. For Crohn's disease patients, a baseline brain MRI may also be helpful (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, the prognosis for patients who develop PML remains poor. The condition is permanent in the sense that neurological damage is typically irreversible. While some patients may survive with aggressive treatment, such as plasma exchange to remove Tysabri from the bloodstream and immune reconstitution, the underlying brain damage often leads to lasting disability. The FDA label's statement that PML "usually leads to death or severe disability" underscores the seriousness of this adverse effect.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Yes, PML from Tysabri is generally permanent. The infection destroys oligodendrocytes, leading to irreversible myelin loss and neurological damage. Most patients who develop PML experience severe disability or death, as stated in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Key risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors increase the likelihood of JC virus reactivation and PML development.
Yes, PML has been reported after discontinuation of Tysabri in patients who had no signs of PML at the time of stopping. The FDA recommends monitoring for at least six months after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.